Updates

High Times: U.S. Military Veterans Are Going to Mexico for Psychedelic Treatment

A recent report by CBS News highlighted this trend, noting that as “ many veterans with PTSD remain desperate for healing, a growing number are turning to psychedelic-assisted treatment in Mexico — using substances the government they fought for says are illegal.”

CBS News: U.S. military veterans turn to psychedelics in Mexico for PTSD treatment

Suicide rates for American service members and veterans are nothing short of catastrophic, with recent estimates claiming almost 17 vets take their own lives in the U.S. every day. Many of them suffer from post-traumatic stress and debilitating brain injuries, which traditional medications have largely failed to cure.

Stars and Stripes: Ecstasy and magic mushrooms show signs of helping with PTSD treatment, researchers say

Researchers and veterans testifying Tuesday on the use of psychedelic drugs to relieve post-traumatic stress disorder and suicidal thoughts urged House lawmakers to back more studies into the alternative treatments.

Newsweek: The Case for Ibogaine: Kentucky's Opportunity to Lead in the Fight Against Opioid Addiction | Opinion

As the opioid epidemic continues to grip our nation, claiming lives, destroying families, and burdening communities, it is imperative that we explore every viable solution. Among these potential solutions is a powerful, natural, non-addictive substance known as ibogaine. As voices that have served in political and military capacities, we unite in our appeal to the Kentucky Opioid Abatement Advisory Commission (KYOAAC): Allocate $42 million for ibogaine research. Kentucky has a unique chance to pioneer a revolutionary approach to combat opioid addiction and pave the way for the entire country.

Lucid News: An Ambitious Vision Drives Kentucky’s Ibogaine Plan to Treat Opioid Dependency

When Bryan Hubbard was appointed Executive Director of the newly formed Kentucky Opioid Abatement Advisory Commission in 2021, he had already been tracking psychedelic-assisted therapies in the media for three years.